Fertility Medical Group, São Paulo, SP, Brazil.
Rev Bras Ginecol Obstet. 2021 Oct;43(10):749-758. doi: 10.1055/s-0041-1736306. Epub 2021 Nov 16.
To investigate whether patients with a previous recombinant follicle stimulating hormone (rFSH)-stimulated cycle would have improved outcomes with rFSH + recombinant luteinizing hormone (rLH) stimulation in the following cycle.
For the present retrospective case-control study, 228 cycles performed in 114 patients undergoing intracytoplasmic sperm injection (ICSI) between 2015 and 2018 in an in vitro fertilization (IVF) center were evaluated. Controlled ovarian stimulation (COS) was achieved with rFSH (Gonal-f, Serono, Geneva, Switzerland) in the first ICSI cycle (rFSH group), and with rFSH and rLH (Pergoveris, Merck Serono S.p.A, Bari, Italy) in the second cycle (rFSH + rLH group). The ICSI outcomes were compared among the groups.
Higher estradiol levels, oocyte yield, day-3 high-quality embryos rate and implantation rate, and a lower miscarriage rate were observed in the rFSH + rLH group compared with the rFSH group. In patients < 35 years old, the implantation rate was higher in the rFSH + rLH group compared with the rFSH group. In patients ≥ 35 years old, higher estradiol levels, oocyte yield, day-3 high-quality embryos rate, and implantation rate were observed in the rFSH + rLH group. In patients with ≤ 4 retrieved oocytes, oocyte yield, mature oocytes rate, normal cleavage speed, implantation rate, and miscarriage rate were improved in the rFSH + rLH group. In patients with ≥ 5 retrieved oocytes, higher estradiol levels, oocyte yield, and implantation rate were observed in the rFSH + rLH group.
Ovarian stimulation with luteinizing hormone (LH) supplementation results in higher implantation rates, independent of maternal age and response to COS when compared with previous cycles stimulated with rFSH only. Improvements were also observed for ICSI outcomes and miscarriage after stratification by age and retrieved oocytes.
研究在接受体外受精(IVF)中心的胞浆内单精子注射(ICSI)的 114 名患者中,在接下来的周期中使用重组卵泡刺激素(rFSH)+重组促黄体生成素(rLH)刺激是否会改善之前 rFSH 刺激周期的患者的结局。
本回顾性病例对照研究评估了 2015 年至 2018 年期间在 IVF 中心进行的 228 个周期。在第一周期的 ICSI 中使用 rFSH(Gonal-f,Serono,瑞士日内瓦)进行控制性卵巢刺激(COS)(rFSH 组),在第二周期中使用 rFSH 和 rLH(Pergoveris,Merck Serono S.p.A,意大利巴里)(rFSH+rLH 组)。比较了各组的 ICSI 结局。
rFSH+rLH 组的雌二醇水平、卵母细胞产量、第 3 天优质胚胎率和着床率更高,流产率更低。在<35 岁的患者中,rFSH+rLH 组的着床率高于 rFSH 组。在≥35 岁的患者中,rFSH+rLH 组的雌二醇水平、卵母细胞产量、第 3 天优质胚胎率和着床率更高。在≤4 个获卵的患者中,rFSH+rLH 组的卵母细胞产量、成熟卵母细胞率、正常卵裂速度、着床率和流产率得到改善。在≥5 个获卵的患者中,rFSH+rLH 组的雌二醇水平、卵母细胞产量和着床率更高。
与仅用 rFSH 刺激的前几个周期相比,添加黄体生成素(LH)的卵巢刺激可提高着床率,且与患者的年龄和对 COS 的反应无关。根据年龄和获卵数进行分层后,ICSI 结局和流产率也得到了改善。